Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- Odiparcil For The Prevention Of Venous Thromboembolism: Complete Statistical AnalysisIndependent statistical analysis of Odiparcil For The Prevention Of Venous Thromboembolism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00244725).
- ODYSSEY ESCAPEIndependent statistical analysis of Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- ODYSSEY FH IIIndependent statistical analysis of Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy): primary endpoint results, effect estimate with confidence…
- ODYSSEY HoFHIndependent statistical analysis of Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03156621).
- ODYSSEY OUTCOMESComplete statistical analysis of ODYSSEY OUTCOMES, the randomized phase 3 trial of alirocumab versus placebo after acute coronary syndrome, including time-to-event endpoints, hazard ratios, stratified log-rank testing, multiplicity, safety, and statistical interpretation.
- Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL): Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval,…
- Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01258933).
- Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Off Clamp Randomization: Complete Statistical AnalysisIndependent statistical analysis of Off Clamp Randomization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01732120).
- Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia: Complete Statistical AnalysisIndependent statistical analysis of Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01408732).
- OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone: Complete Statistical AnalysisIndependent statistical analysis of OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- OHR-3Independent statistical analysis of Safety for Frequent Use Conditions of Hair Removal Device: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01348789).
- OHTSIndependent statistical analysis of Ocular Hypertension Treatment Study (OHTS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00000125).
- OIIndependent statistical analysis of Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- OISO-1Independent statistical analysis of Comparison of Three Techniques for Ultrasound-guided Internal Jugular Cannulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01966354).
- OKQ2Independent statistical analysis of One Key Question: Pilot Study at NorthShore: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03947788).
- OLAIndependent statistical analysis of Oligonucleotide Ligation Assay (OLA) Resistance Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01898754).
- Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study: Complete Statistical AnalysisIndependent statistical analysis of Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery: primary endpoint results, effect estimate with…
- Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03570476).
- Olaparib in Adults With Recurrent/Metastatic Ewing’s Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01583543).
- Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis: Complete Statistical AnalysisIndependent statistical analysis of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05286827).
- Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- OLAPCOIndependent statistical analysis of OLAParib COmbinations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02576444).
- OLEIndependent statistical analysis of Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- OLE-IEDATIndependent statistical analysis of Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- OLE2Independent statistical analysis of An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10): Complete Statistical AnalysisIndependent statistical analysis of Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01294241).
- OLFUS-VIPESIndependent statistical analysis of Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- OLIFIndependent statistical analysis of OptiMesh® for Lumbar Interbody Fusion Trial (OLIF): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00764491).
- oligo-metsIndependent statistical analysis of A Study of Definitive Therapy to Treat Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02716974).
- OLIGOPELVISIndependent statistical analysis of Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- OLIVERIndependent statistical analysis of Evaluation of Bispectral Index (BIS™) and Levels of Sedation With Common Inhalational Anesthetics in Healthy Volunteers (OLIVER): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Olmesartan Comparison to Losartan in Hypertensive Subjects: Complete Statistical AnalysisIndependent statistical analysis of Olmesartan Comparison to Losartan in Hypertensive Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00949884).
- Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- OLOLIndependent statistical analysis of Our Lifestyles Our Lives: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02965729).
- Olopatadine Eye Drops and Allergy Skin Testing: Complete Statistical AnalysisIndependent statistical analysis of Olopatadine Eye Drops and Allergy Skin Testing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00775658).
- Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction – DOSE Finding Study: Complete Statistical AnalysisIndependent statistical analysis of Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- OLTERMSIndependent statistical analysis of Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- OlympiAComplete statistical analysis of the OlympiA phase 3 trial of adjuvant olaparib versus placebo in patients with germline BRCA-mutated high-risk HER2-negative primary breast cancer, including trial design, time-to-event endpoints, statistical methods, reported…
- OLYMPIAIndependent statistical analysis of TearCare System to Treat Dry Eye Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03857919).
- OlympiADIndependent statistical analysis of the OlympiAD phase 3 trial of olaparib monotherapy versus physician's choice chemotherapy in metastatic breast cancer patients with germline BRCA1/2 mutations.
- OlympiADIndependent statistical analysis of Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.: primary endpoint results,…
- OLYMPUSIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational Study: Complete Statistical AnalysisIndependent statistical analysis of Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…